R
28.78
-0.94 (-3.16%)
| 前收盘价格 | 29.72 |
| 收盘价格 | 29.20 |
| 成交量 | 5,616,037 |
| 平均成交量 (3个月) | 7,135,921 |
| 市值 | 20,597,878,784 |
| 价格/销量 (P/S) | 1.48 |
| 股市价格/股市净资产 (P/B) | 4.79 |
| 52周波幅 | |
| 利润日期 | 6 Feb 2026 |
| 营业利益率 (TTM) | -4,823.84% |
| 稀释每股收益 (EPS TTM) | -0.750 |
| 季度收入增长率 (YOY) | -16.10% |
| 季度盈利增长率 (YOY) | -96.70% |
| 总债务/股东权益 (D/E MRQ) | 1.93% |
| 流动比率 (MRQ) | 33.47 |
| 营业现金流 (OCF TTM) | -839.45 M |
| 杠杆自由现金流 (LFCF TTM) | -375.20 M |
| 资产报酬率 (ROA TTM) | -10.73% |
| 股东权益报酬率 (ROE TTM) | -12.54% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Roivant Sciences Ltd. | 看涨 | 看涨 |
AIStockmoo 评分
1.6
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.63 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 30.31% |
| 机构持股比例 | 83.49% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Qvt Financial Lp | 31 Dec 2025 | 26,387,021 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 35.00 (Citigroup, 21.61%) | 购买 |
| 中 | 33.00 (14.66%) | |
| 低 | 30.00 (Guggenheim, 4.24%) | 购买 |
| 平均值 | 32.80 (13.97%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 25.67 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (18.14%) | 购买 | 29.52 |
| 10 Feb 2026 | 33.00 (14.66%) | 购买 | 27.35 | |
| Citigroup | 10 Feb 2026 | 35.00 (21.61%) | 购买 | 27.35 |
| Guggenheim | 09 Feb 2026 | 30.00 (4.24%) | 购买 | 27.67 |
| Goldman Sachs | 15 Dec 2025 | 33.00 (14.66%) | 购买 | 21.90 |
| Leerink Partners | 15 Dec 2025 | 32.00 (11.19%) | 购买 | 21.90 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合